LDL-C goal attainment with the addition of ezetimibe to on-going simvastatin treatment in coronary heart disease patients with hypercholesterolemia

200544 citationsJournal Article

Authors

C. Brohet · Cliniques Universitaires Saint-Luc

Shmuel Banai

A. Marco Alings · Amphia Ziekenhuis

Rachid Massaad · Merck & Co., Inc., Rahway, NJ, USA (United States)

Michael J. Davies · Merck & Co., Inc., Rahway, NJ, USA (United States)

Christopher Allen · Merck & Co., Inc., Rahway, NJ, USA (United States)

Abstract

Ezetimibe co-administered with on-going simvastatin 10 mg or 20 mg treatment enabled more CHD patients with hypercholesterolemia to attain the LDL-C treatment target of </= 2.60 mmol/L.

Topics & Keywords

Lipoproteins and Cardiovascular Health Computational Drug Discovery Methods Diabetes, Cardiovascular Risks, and Lipoproteins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Current Medical Research and Opinion

Volume 21, Issue 4, pp. 571-578

DOI: 10.1185/030079905x382004

Field-Weighted Citation Impact: 6.48